Chemotherapy (cisplatin) converts resting platelet into a pyroptotic state. Cisplatin triggers activation of caspase-3. Active caspase-3 cleaves full-length gasdermin E (GSDME) to generate GSDME–N-terminal and GSDME–C-terminal fragments. GSDME–N-terminal protein is recruited to the platelet lipid raft membrane via an interaction with flotillin-2. GSDME–N-terminal protein assembles into pores in the raft fraction and causes leakage of platelet granular contents. Increased platelet secretion triggers platelet aggregation and thrombosis. Professional illustration by Somersault18:24.

Chemotherapy (cisplatin) converts resting platelet into a pyroptotic state. Cisplatin triggers activation of caspase-3. Active caspase-3 cleaves full-length gasdermin E (GSDME) to generate GSDME–N-terminal and GSDME–C-terminal fragments. GSDME–N-terminal protein is recruited to the platelet lipid raft membrane via an interaction with flotillin-2. GSDME–N-terminal protein assembles into pores in the raft fraction and causes leakage of platelet granular contents. Increased platelet secretion triggers platelet aggregation and thrombosis. Professional illustration by Somersault18:24.

Close Modal

or Create an Account

Close Modal
Close Modal